BruceEricSandsMD

PubMed

• 1 citations
  Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
  Markus Friedrich Neurath, Bruce Eric Sands, Florian Rieder
  Gut. 2024-12-10
• 2 citations
  Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
  Geert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, Bruce E Sands, Scott Lee
  Inflammatory Bowel Diseases. 2024-12-05
• 6 citations
  Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
  Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns
  Inflammatory Bowel Diseases. 2024-12-05

Journal Articles

• Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  
  Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
• Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  
  Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
• Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults  
  Gary R Lichtenstein, Bruce E Sands, Miguel D Regueiro, Kim L Isaacs, Nature
• Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-Disciplinary Consensus  
  Peter D Higgins, Corey A Siegel, Bruce E Sands, Journal of Crohn's and Colitis
• High-Dose Infliximab Therapy in Crohn’s Disease: Clinical Experience, Safety, and Efficacy  
  Hendler SA, Cohen BL, Colombel JF, Sands BE, Mayer L, Agarwal S, J Crohns Colitis, 1/24/2014
• Menstrual cycle changes in women with inflammatory bowel disease: a study from the Ocean State Crohn’s and Colitis Area Registry  
  Saha S, Zhao YQ, Shah SA, Esposti SD, Lidofsky S, Salih S, Bright R, Law M, Moniz H, Flowers N, Merrick M, Sands BE, Inflamm Bowel Di, 1/21/2014
• SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease  
  Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands BE, Daly MJ, Xavier RJ, Yajnik V, J Crohns Colitis, 1/1/2014
• Anti-TNF therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis  
  Narula N, Al-Dabbagh R, Dhillon A. Sands BE, Marshall JK, Inflamm Bowel Dis, 1/1/2014
• Reliability and initial validation of the ulcerative colitis endoscopic index of severity  
  Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Be..., Gastroenterology, 1/1/2013
• Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?  
  Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS, Inflamm Bowel Dis, 1/23/2012
• Secukinumab, a human anti-IL- 17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial  
  Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellga..., Gut, 1/17/2012
• Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and -2 extension studies  
  Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, San..., Inflamm Bowel Dis, 1/1/2012
• Adverse events do not outweigh benefits of combination therapy for Crohn’s disease: a decision analytic model  
  Siegel CA, Finlayson SR, Sands BE, Tosteson ANA, Clin Gastroenterol Hepatol, 1/1/2012
• Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)  
  Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lemann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, B..., Gut, 1/1/2012
• Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians  
  Saha S, Lam M, Roberson E, Shah S, LeLeiko NS, Lidofsky S, Bright R, Flowers N, Merrick M, Sands BE, Med Health RI, 1/1/2012
• Abatacept for Crohn’s disease and ulcerative colitis  
  Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB, Gastroenterology, 1/1/2012
• Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment  
  Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, Leleiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C, Genome Biol, 1/1/2012
• Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease  
  Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJS, Panaccione R, Greenberg G, Schreibe..., N Engl J Med, 1/1/2012
• Development of the Crohn’s disease digestive damage score, the Lemann score  
  Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D’Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Miche..., Inflamm Bowel Dis, 1/17/2011
• Immediate versus Tailored Prophylaxis to Prevent Symptomatic Recurrences After Surgery for Ileocecal Crohn’s Disease?  
  Bordeianou L, Stein SL, Ho VP, Bursun A, Sands BE, Korzenik JR, Hodin RA, Surgery, 1/1/2011
• Real-Time Tool to Display the Predicted Disease Course and Treatment Response for Children with Crohn’s Disease  
  Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR,..., Inflamm Bowel Dis, 1/1/2011
• Characterization of Patients with Infliximab Induced Lupus Erythematosus and Outcomes After Re-Treatment with a Second Anti-TNF Agent  
  Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR, Inflamm Bowel Dis, 1/1/2011
• Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis  
  Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ, Gastroenterology, 1/1/2011
• Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in Patients with Inflammatory Bowel Disease  
  Tinsley A, Macklin E, Korzenik J, Sands BE, Aliment Pharmacol Ther, 1/1/2011
• IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010—Inflammatory Bowel Disease Task Force ...  
  Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D’Haens G, Dotan I, Goh KL, Hibi T, Kozarek RA, Quigley EM, Reinisch W, Sands BE, Sollano JD, Steinhart AH, ..., Inflamm Bowel Dis, 1/1/2011
• Join now to see all

Books/Book Chapters

• Mount Sinai Expert Guides: Gastroenterology 
  Sands, BEWiley Blackwell, Hoboken, NJ2015
• Pocket Guide to IBD 
  Chapter: Foreword 
  Sands BEEditors: Kane SV and Dubinsky MC.SLACK, Inc., Thorofare, NJ2011
• Inflammatory Bowel Disease. Translating basic science into clinical practice 
  Chapter: Crohn’s Disease: Clinical Course and Complications 
  Page 235 - 251Sands BEEditors: S.R. Targan, F. Shanahan, L.C. Karp.Wiley-Blackwell, Hoboken, NJ2010
• Sleisenger & Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management 
  Chapter: Crohn’s Disease 
  Page 1941 - 1973Sands BE, Siegel CAEditors: M. Feldman, L.S. Friedman, L.J. Brandt.Saunders, Philadelphia, PAEdition 9th,2010
• IBD Yearbook 
  Chapter: Forward 
  Sands BERemedica, Chicago, IL2008
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management 
  Chapter: Crohn’s Disease 
  Page 2459 - 2498Sands BEEditors: M. Feldman, L.S. Friedman, L.J. Brandt.Saunders, Philadelphia, PAEdition 8th,2006
• The NASPGHAN IBD Book for Families 
  Chapter: New Therapies in Trials in Adults 
  Sands BEEditors: KJ Benkov.2004
• MGH Ambulatory Care Syllabus 
  Forcione DG, Cohen AM, Sands BE. Chronic Diarrhea. E Basch, W Messersmith, S Birnbaum, C GarzaEdition 4th,2004
• Kirsner’s Inflammatory Bowel Disease 
  Chapter: Differential diagnosis of inflammatory bowel disease 
  Page 359 - 379Forcione DG, Sands BEEditors: R.B. Sartor, W.J. Sandborn.Saunders, Philadelphia, PA2004
• Inflammatory Bowel Diseases: Diagnosis & Therapeutics 
  Chapter: Etiology and Pathogenesis of Inflammatory Bowel Disease 
  Page 33 - 63Farrell JJ, Sands BEEditors: Cohen R and Wu G.Humana Press, Totowa, NJ2003
• The Inflammatory Bowel Disease Yearbook 
  Chapter: Biological Therapies 
  Forcione DG, Sands, BEEditors: Bernstein CB.Remedica, London, UK2003
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management 
  Chapter: Crohn’s Disease 
  Page 2005 - 2038Sands BEEditors: M. Feldman, L.S. Friedman, M.H. Sleisenger.Saunders, Philadelphia, PAEdition 7th,2002
• Seminars in Gastrointestinal Diseases 
  Chapter: Inflammatory Bowel Disease 
  Page 209 - 292Sands BEEditors: Sleisenger MH, ed., Rockey DC, Wilcox CM, assoc..2001
• The Harvard Medical School Family Health Guide 
  Sands BEEditors: Anthony L. Komaroff, M.D..Simon & Schuster, New York, NY1998
• Join now to see all

Abstracts/Posters

• An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele
  Forcione DG, Sands B, Isselbacher KJ, Rustgi A, Podolsky DK, Pillai S, Proc Natl Acad Sci U S A, 1/1/1996

Lectures

• Postoperative Recurrence: How Do I Minimize Risk? 
  Miami, FL - 1/1/2014
• Treating Ulcerative Colitis with New Biologic Therapies 
  San Diego, CA - 1/1/2013
• Biologics 101 
  San Diego, CA - 1/1/2013
• Iron Deficiency Anemia in Modern Gastroenterology Practice: Prevalence and Implications 
  San Diego, CA, 2013; Hollywood, FL, 2013 - 1/1/2013
• Integrins and Addressins in IBD: Examining the Evidence 
  San Diego, FL - 1/1/2013
• What to do when anti-TNFs don’t work 
  San Diego, CA - 1/1/2013
• Fundamentals of Trail Design 
  Gaithersburg, MD - 1/1/2013
• GI tract infections in IBD: Detection and treatment of Clostridium difficile, CMV and enteric pathogens: case studies 
  Hollywood, FL - 1/1/2013
• Evolving Treatment Paradigms in IBD 
  Atlanta, GA - 1/1/2013
• Changing Treatment Paradigms in the Inflammatory Bowel Diseases 
  Morristown, NJ - 1/1/2013
• Personalizing Approaches to IBD Therapy 
  New York, NY - 1/1/2013
• Management of IBD in the Hospitalized Patient 
  New York, NY - 1/1/2013
• Safety and Complications in Biologics Treatment for IBD 
  Tokyo, Japan - 1/1/2013
• Advances in IBD 
  New York, NY - 1/1/2013
• Breaking Through: The Most Likely Next Available IBD Treatments 
  Orlando, FL - 1/1/2013
• Current Topics in the Inflammatory Bowel Diseases 
  Babylon, NY - 1/1/2012
• Current Controversies in the Inflammatory Bowel Diseases 
  New York, NY - 1/1/2012
• Optimization of biologic treatment in biologic naïve patients 
  New York, NY - 1/1/2012
• Balancing and explaining risks of therapy in patients’ treatment options 
  New York, NY - 1/1/2012
• How do I approach a refractory patient with IBD? 
  New Brunswick, NJ - 1/1/2012
• Evolving Treatment Paradigms in Inflammatory Bowel Disease 
  New York, NY - 1/1/2012
• The risks and benefits of early immunosuppression and biological therapy 
  Basel, Switzerland - 1/1/2012
• Changing Paradigms in the Treatment of Inflammatory Bowel Disease 
  St. Louis, MO - 1/1/2012
• Clinical Challenge: Managing the Complicated IBD Patient 
  San Diego, CA - 1/1/2012
• Appropriate timing of introduction of new therapies 
  Amsterdam, Netherlands - 1/1/2012
• Join now to see all

Other

• The Facts About Inflammatory Bowel Diseases 
  Sands BE, Crohn’s and Colitis Foundation of America
  1/1/2011
• Quality of Care in IBD 
  Sands BE, Siegel CA, Kappelman M, Crohn’s and Colitis Foundation’s Clinical and Research Conference
  Hollywood, FL - 1/10/2010
• Biologics in IBD: Do the Risks Outweigh the Benefits? 
  Sands BE, AGA Perspectives
  1/1/2010
• Risk of Lymphoma Associated with Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn’s Disease 
  Kuemmerle JF, Sands BE
  http://www.gastro.org/user-assets/Audio/Journal_Podcast/CGH/CGH_Podcast_August_2009.mp3
  1/1/2009
• Clinical Pearls from ACG 2006: Advances in the Diagnosis, Staging, and Treatment of Crohn’s Disease 
  Sands BE, CME- and CPE-Certified Newsletter
  1/17/2006
• Master Classes in Gastroenterology: Controversies in Crohn’s Disease 
  Sands, B.E., Slide Library
  1/1/2006
• Anti-TNF Therapy: Current Trends in the Management of Crohn’s Disease 
  Sands BE
  1/31/2005
• The Definition, Diagnosis, and Treatment of Moderate Ulcerative Colitis 
  Hanauer SB, Abreu MT, Lichtenstein GR, Kornbluth A, Present DH, Sands BE, CME White Paper, University of Chicago School of Medicine, Department of Continuing Medical Educat
  1/1/2005
• Mild, Moderate, Severe Disease: What is it, why is it important? 
  Sands BE, Crohn’s & Colitis Foundation of America, New England Chapter Newsletter
  1/1/2005
• Novel Therapies in the Human Model of IBD: What have we learned about pathogenesis? 
  Sands, B.E., Harrison’s Online
  1/1/1998
• Emerging Role of Biologic Therapies in IBD 
  Sands, B.E., Rutgeerts, P., Slide Library
  Yardley, PA
• Join now to see all